Expert Analysis

Pharmacology and Adverse Events

Source: CCO Independent Conference Coverage of the 2005 International AIDS Society Conference on HIV Pathogenesis and Treatment*

*CCO is an independent medical education company that provides state-of-the-art medical information to healthcare professionals through conference coverage and other educational programs.

Pharmacology and Adverse Events

Program Director: John P. Phair, MD

Faculty:

Terrence F. Blaschke, MD
Courtney V. Fletcher, PharmD
William G. Powderly, MD

CREDIT INFORMATION

Release Date: 09/23/05

Expiration Date: 09/22/06

Physicians: maximum of 1.25 AMA PRA Category 1 Credits™

Registered Nurses: 1.6 Nursing contact hours

Pharmacists: 1.4 contact hours (0.14 CEUs)

Status: Please log in to view status

Learning Objectives

Upon completion of this activity, participants should be able to:

Describe recent data on drug-drug interactions between antiretroviral agents.
Review data on adverse effects associated with the use of Highly Active Antiretroviral Therapy (HAART).
Discuss novel dosing regimens for administration of lopinavir/ritonavir in adults and children.

Topics covered include:

Once-Daily vs Twice-Daily Lopinavir/Ritonavir
Novel Lopinavir/Ritonavir Formulation
Pharmacokinetics of Lopinavir/Ritonavir in Pediatric Patients
Interactions Between Vicriviroc and Other Antiretrovirals
Evaluating Content and Bioequivalence of Generics
Toxicity Due to Use of Rifampin With Antiretrovirals
Adverse Events and Mortality
Renal Toxicity in HAART-Treated Patients
Thyroid Disease in HIV Infection

Disclaimer: The materials published on the Clinical Care Options Web site reflect the views of the reviewers or authors of the CCO material, not those of Clinical Care Options, LLC, the CME provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.